VivoSeq
Gastroenterology

Moderate to Severe Crohn's Disease

1

Pipeline Programs↗

3

Active Trials↗

17

Companies Involved↗

Moderate to Severe Crohn's Disease is an early-stage landscape with 1 program across 17 companies. The most active players are AstraZeneca, Takeda, Amgen.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

62/100

Attrition Rate

35/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 2Takeda logo

Takeda

0 programs

PreclinicalAmgen logo

Amgen

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalFerring logo

Ferring

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

AZD7798

AstraZeneca

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

43

clinical trials

Completed24 · 56%
Terminated14 · 33%
Recruiting2 · 5%
Unknown status1 · 2%
Withdrawn1 · 2%
Active, not recruiting1 · 2%

Clinical Trials

Trial Activity

43 trials

A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Recruiting·Takeda logoTakeda·Phase 3·NCT05837897·408 enrolled
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Recruiting·Takeda logoTakeda·Phase 3·NCT04779320·120 enrolled
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients With Moderate to Severe Crohn's Disease
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT06450197·120 enrolled
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
Completed·Pfizer logoPfizer·Phase 2·NCT03395184·244 enrolled
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
Completed·Ferring logoFerring·Phase 2·NCT00739986·152 enrolled
A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
Completed·Pfizer logoPfizer·Phase 2·NCT00615199·139 enrolled
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Completed·Takeda logoTakeda·Phase 3·NCT00783692·1,116 enrolled
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
Completed·Takeda logoTakeda·Phase 3·NCT01224171·416 enrolled
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT02531113·69 enrolled
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
Completed·AAbbott·Phase 3·NCT00338650·1,000 enrolled
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
Completed·Sanofi logoSanofi·Phase 3·NCT00206674·286 enrolled
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
Completed·AAbbott·Phase 3·NCT00409682·192 enrolled
Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease
Completed·Amgen logoAmgen·Phase 2·NCT01696396·254 enrolled
A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
Completed·Amgen logoAmgen·Phase 2·NCT00306215·436 enrolled
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
Completed·AbbVie logoAbbVie·Phase 3·NCT02499783·205 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)